Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in key investor conferences in May 2022. Scheduled events include the JP Morgan Conference on May 16, featuring a fireside chat with CEO Yujiro Hata, and the Guggenheim Synthetic Lethality Day, also on May 16, where Hata will participate in panel discussions. The Citi Biopharma Virtual Co-Panel Day is set for May 18. Interested parties can access live audio webcasts and replays on IDEAYA's website. IDEAYA specializes in synthetic lethality-focused precision medicine for targeted cancer therapeutics.

IDEAYA Biosciences (NASDAQ: IDYA) announced that the FDA has granted orphan-drug designation to darovasertib, a potential first-in-class PKC inhibitor, for treating uveal melanoma. This designation provides IDEAYA with tax credits, user fee exemptions, and seven years of marketing exclusivity post-approval. IDEAYA plans to update clinical data related to the darovasertib and crizotinib combination in mid-2022 and seeks FDA guidance for a registration-enabling trial design. Over 200 patients have been evaluated, with ongoing trials targeting additional oncology indications.

IDEAYA Biosciences has announced the appointment of Dr. Catherine Mackey to its Board of Directors. With over 30 years of experience in life sciences, Dr. Mackey previously held senior roles at Pfizer and has an extensive background in oncology research and development. Her expertise is expected to enhance IDEAYA's synthetic lethality platform and support the advancement of its drug pipeline, particularly the Phase 1 MAT2A inhibitor IDE397 and Phase 2 PKC inhibitor darovasertib. This strategic addition aims to drive progress in the company’s targeted therapeutics initiatives.

IDEAYA Biosciences (NASDAQ: IDYA) reported a strong financial position with approximately $368 million in cash as of December 31, 2021, sufficient to fund operations into 2025. The company is actively enrolling patients in Cohort 6 of the IDE397 clinical trial, revealing no serious drug-related adverse events. IDEAYA aims to expand its monotherapy and combination cohorts for IDE397 by mid-2022. Additionally, promising results from the darovasertib and crizotinib combination therapy have shown a 100% disease control rate in uveal melanoma patients, showcasing robust clinical activity and manageable side effects.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced promising interim Phase 1 clinical data for IDE397, a MAT2A inhibitor targeting solid tumors with MTAP gene deletions. The trial showed preclinical tumor SDMA suppression of 95-100% and robust plasma SAM modulation exceeding a 60% reduction. Cohort 5 reports a 95% reduction in tumor SDMA without drug-related serious adverse events. IDEAYA is expanding into monotherapy cohorts and targeting a data package delivery to GSK by mid-2022, potentially earning a $50 million option payment and up to $465 million in milestones.

IDEAYA Biosciences (IDYA) has collaborated with Pfizer (PFE) to enhance clinical trials evaluating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM) and cMET-driven tumors. The Phase 2 trial could enable registration, with promising preliminary data showing robust activity. IDEAYA plans to provide an update on clinical data in mid-2022 and will seek FDA guidance for trial design. This partnership aims to elevate treatment standards for patients with high unmet needs and potentially expand to other cancer types.

IDEAYA Biosciences (NASDAQ: IDYA) is set to host an Investor Webcast on March 15, 2022, to discuss interim clinical data for IDE397, a potential MAT2A inhibitor in a Phase 1 clinical trial. This trial focuses on patients with tumors featuring MTAP deletions. The call will cover dose escalation data, adverse events, and pharmacokinetic information, alongside the financial results for Q4 and the full year 2021. The company emphasizes its commitment to precision oncology through targeted therapeutic development.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in several investor conferences in March 2022. Key events include the Guggenheim 3rd Annual Healthy Altitudes CEO Summit on March 10, the Oppenheimer Targeted Oncology Panel on March 14, and the 34th Annual Roth Conference on the same day. CEO Yujiro Hata and CFO Paul Stone will represent the company. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days following the events.

IDEAYA Biosciences (NASDAQ: IDYA) announced participation in Guggenheim Oncology Day on February 9, 2022, at 3:30 PM ET. CEO Yujiro Hata will engage in a fireside chat hosted by Charles Zhu, Ph.D. A live audio webcast will be accessible through IDEAYA’s website, with a replay available for 30 days post-event. IDEAYA focuses on precision medicine for oncology, utilizing synthetic lethality to develop targeted therapeutics based on molecular diagnostics. For more details, visit the Investor Calendar.